Business Outlook: Leschly on to a winner in going for an encore

Bigger and more ambitious still grow the consolidating mergers of industry and finance. After months of fevered stock market speculation, Jan Leschly, chief executive of SmithKline Beecham, finally admitted publicly for the first time yesterday to plans for the big daddy of them all - a prospective merger with American Home Products to form a pharmaceuticals and health care products goliath with a combined market capitalisation of pounds 77bn. Just to put this in perspective, that's getting on for double the annual GDP of Ireland.

This is the world's most ambitious merger to date and it would be silly to try and belittle it in any way. All the same, by the end of the year we are going to have seen a lot more of these things, both domestic and like this one cross border in nature. It is all too likely that soon it will be eclipsed by something even bigger. The backdrop to this growing wave of mergers, not just in pharmaceuticals but across industries, sectors and frontiers, is well rehearsed. Globalisation, rapid technological change and a relentless pressure on managements for enhanced returns, is forcing the pace as never before.

Even so, it is somehow appropriate that it should be Mr Leschly who is out of the hatch first this year. He was not the architect of the original merger between Beecham and SmithKline, but he is credited with being the one who made it work, adding hugely to shareholder value in the process. Now this tough talking Dane is intent on performing an encore. He knows how to do these things and he knows how much value they can create.

Pharmaceuticals is in many respects already a truly global industry, in the sense that any company which can offer a medical advance will find its product used all over the world. Despite this and some already wopping pharmaceutical mergers, such as that between Glaxo and Wellcome three years ago, it is still a surprisingly fragmented industry, with no single company accounting for much more than 5 per cent of the world prescribed drugs market.

Actually what SmithKline is attempting here is not so much a quantum leap in size for pharmaceutical companies as a catching up with the market leaders. Even if Mr Leschly pulls this off, he still won't be quite as big as Merck. Nor will he be significantly larger in terms of sales and market capitalisation than Novartis, Pfizer and Glaxo Wellcome. But what he does do is achieve their economies of scale, and, just as important in this industry, their level of spend on research and development.

It is still sometimes the case that the boffin in his end of the garden shed will stumble across some new breakthrough in medical science. The biotechs are good examples of how this random approach to the blockbuster pharmaceutical product can still work. But on the whole this is not how it is done these days. New treatments for common ailments are achieved via very costly, systematic and targeted research into particular molecular structures, compounds and substances. Moreover, the costs of bringing a promising new compound from discovery to market are generally too big for anyone but the biggest players. So size matters.

The idea that there is no room any longer for the middle-ranked player, strongly locked into a particular domestic market, has become a bit of a business cliche. Companies have to be either the big global operator, with the distribution, spending and marketing clout to reach out to the mass markets of the world, or they they must position themselves as small niche players, sniping at the soft underbelly of the international monopolists. Perhaps unfortunately, it is nonetheless true. Mr Leschly is aiming to put SmithKline Beecham firmly in the first category.

Start your day with The Independent, sign up for daily news emails
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...

Guru Careers: C# Project Team Lead

£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...

Guru Careers: Graduate Editor / Editorial Assistant

£16 - 20k: Guru Careers: A Graduate Editor / Editorial Assistant is needed to ...

Day In a Page

Blundering Tony Blair quits as Middle East peace envoy – only Israel will miss him

Blundering Blair quits as Middle East peace envoy – only Israel will miss him

For Arabs – and for Britons who lost their loved ones in his shambolic war in Iraq – his appointment was an insult, says Robert Fisk
Fifa corruption arrests: All hail the Feds for riding to football's rescue

Fifa corruption arrests

All hail the Feds for riding to football's rescue, says Ian Herbert
Isis in Syria: The Kurdish enclave still resisting the tyranny of President Assad and militant fighters

The Kurdish enclave still resisting the tyranny of Assad and Isis

In Syrian Kurdish cantons along the Turkish border, the progressive aims of the 2011 uprising are being enacted despite the war. Patrick Cockburn returns to Amuda
How I survived Cambodia's Killing Fields: Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape the US

How I survived Cambodia's Killing Fields

Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape to the US
Stephen Mangan interview: From posh buffoon to pregnant dad, the actor has quite a range

How Stephen Mangan got his range

Posh buffoon, hapless writer, pregnant dad - Mangan is certainly a versatile actor
The ZX Spectrum has been crowd-funded back into play - with some 21st-century tweaks

The ZX Spectrum is back

The ZX Spectrum was the original - and for some players, still the best. David Crookes meets the fans who've kept the games' flames lit
Grace of Monaco film panned: even the screenwriter pours scorn on biopic starring Nicole Kidman

Even the screenwriter pours scorn on Grace of Monaco biopic

The critics had a field day after last year's premiere, but the savaging goes on
Menstrual Hygiene Day: The strange ideas people used to believe about periods

Menstrual Hygiene Day: The strange ideas people once had about periods

If one was missed, vomiting blood was seen as a viable alternative
The best work perks: From free travel cards to making dreams come true (really)

The quirks of work perks

From free travel cards to making dreams come true (really)
Is bridge the latest twee pastime to get hip?

Is bridge becoming hip?

The number of young players has trebled in the past year. Gillian Orr discovers if this old game has new tricks
Long author-lists on research papers are threatening the academic work system

The rise of 'hyperauthorship'

Now that academic papers are written by thousands (yes, thousands) of contributors, it's getting hard to tell workers from shirkers
The rise of Lego Clubs: How toys are helping children struggling with social interaction to build better relationships

The rise of Lego Clubs

How toys are helping children struggling with social interaction to build better relationships
5 best running glasses

On your marks: 5 best running glasses

Whether you’re pounding pavements, parks or hill passes, keep your eyes protected in all weathers
Joe Root: 'Ben Stokes gives everything – he’s rubbing off on us all'

'Ben Stokes gives everything – he’s rubbing off on us all'

Joe Root says the England dressing room is a happy place again – and Stokes is the catalyst
Raif Badawi: Wife pleads for fresh EU help as Saudi blogger's health worsens

Please save my husband

As the health of blogger Raif Badawi worsens in prison, his wife urges EU governments to put pressure on the Saudi Arabian royal family to allow her husband to join his family in Canada